Navigation Links
Rasheda Ali to Join Advisory Board of Brainstorm Cell Therapeutics
Date:10/16/2007

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- BrainStorm Cell Therapeutics Inc. (OTC Bulletin Board: BCLI), a leading developer of adult stem cell technologies and therapeutics, is excited and honored to state the appointment of Rasheda Ali, revered author and daughter of renowned boxer and long time Parkinson's sufferer Muhammad Ali, as a member of the company's Advisory Board. BrainStorm has announced results leading to a possible cure for Parkinson's, which drew the attention of philanthropist Ali, an advocate in finding a cure for her father's debilitating disease.

As the author of I'll Hold Your Hand So You Won't Fall - a Child's Guide to Parkinson's Disease her longtime goal has been to encourage a dialogue between parents and children. Continuing her efforts toward national and international awareness and pursuing medical breakthroughs for Parkinson's, she will now champion Brainstorm's research and advancements, in her new role.

"I am very excited to be part of the BrainStorm Advisory Board and focus more attention on spotlighting their groundbreaking research towards a cure for Parkinson's," says Ali. "This is obviously a very personal issue for me, as I continue to pray daily for a cure for my father, which it seems BrainStorm is determined to find. I cannot wait to lend a hand."

"As a role model and a living example of how to cope with her own father's struggle with Parkinson's, Rasheda is a natural fit for our cause. We are very excited to have her collaborate with BrainStorm as a pivotal member of our Advisory Board, joining the ranks of notable world class business leaders like Prof. Jacob Frenkel and Harvey Krueger," commented Chaim Lebovits, President. "We know through her passion to find a cure for her father, she will continue to do great things for those who suffer from Parkinson's -- both family and patient."

Leveraging her celebredom and humanitarian legacy, Rasheda wants to bring further awareness to the Parkinson's issue. Over 1 million Americans suffer from Parkinson's, with more victims, young and old, being diagnosed daily. 40% of victims are under the age of 60 and it is estimated that Parkinson's costs the U.S. over $26 billion annually in disability costs and lost productivity. Currently, there is no cure for Parkinson's though BrainStorm Cell Therapeutics is well on its way to conquering this horrible disease via adult stem cell research.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an early stage company engaged in developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson's disease, although its technology may have promise for treating several other diseases including MS and Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete the financings described in this press release and its ability to satisfy all of the closing conditions. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; limited cash resources and its need to raise additional capital to execute on its business plan and continue operations; dependence on its license to Ramot's technology and ability to meet its funding and payment obligations included in such license agreement; ability, together with its licensor, to adequately protect the NurOwn(TM) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.

Contact: Alyssa Miller

(212) 584-4290; amiller@5wpr.com


'/>"/>
SOURCE BrainStorm Cell Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WHO lifts HongKong advisory
2. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
3. Doctors Said – ‘Stop Pressurising NHS Advisory Bod’
4. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
5. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
6. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
7. LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation
8. Study casts doubt on keyboard ills
9. Who Board To Discuss Asian Tsunami Related Health Issues
10. Abdominal Crunches Not The Best Option For Wash Board Abs.
11. Computer Keyboards In Hospitals Could Spread Infection To Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine ... services to families and business owners in the greater Dallas metropolitan area, is ... Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals in ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Sharon Kleyne, ... Global Climate Change and Your Health on Voice of America, declared on her radio ... call attention to the fact that when these bullies attack leaders in corporate America, ...
(Date:12/7/2016)... ... 07, 2016 , ... 1105 Media’s Live From program has ... Awards competition. Live From won in the Use of Social Media category. The ... projects undertaken by the media industry’s most innovative marketing professionals. , ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
(Date:12/7/2016)... Va. (Dec. 3, 2016) , ... (PRWEB) December ... ... nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, was ... in New Mexico with a patient engagement program. New Mexico has more people ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)...   Arena Pharmaceuticals, Inc. (NASDAQ: ... in the ralinepag phase 2 trial.  Ralinepag is an ... for the treatment of pulmonary arterial hypertension (PAH). The ... "This marks an important step in the development ... on our pipeline," said Amit Munshi , Arena,s ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... LONDON , Dec. 7,2016  Based ... drug delivery industry, Frost & Sullivan recognizes ... Frost & Sullivan Award for Enabling Technology ... plug the loopholes in traditional drug delivery ... and liquid microneedle-based drug delivery technologies, Memspatch ...
Breaking Medicine Technology: